Who is sponsoring NCT00471471?

NCT00471471 is sponsored by Ahmad Tarhini.

What condition does NCT00471471 study?

NCT00471471 studies Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin).

What drugs are being tested in NCT00471471?

Interventions: Peptide vaccine, GM-CSF, PF3512676.

What is the status of NCT00471471?

NCT00471471 is currently COMPLETED.

Last reviewed 2017-06-21 · How we verify

Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma

NCT00471471 Phase 1 COMPLETED

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.

Details

Lead sponsor	Ahmad Tarhini
Phase	Phase 1
Status	COMPLETED
Enrolment	22
Start date	2008-10
Completion	2011-12

Conditions

Intraocular Melanoma
Malignant Conjunctival Neoplasm
Melanoma (Skin)

Interventions

Peptide vaccine
GM-CSF
PF3512676

Primary outcomes

Safety — up to 1 year
Number of grade 2 or greater allergic reactions (including generalized urticaria) or any grade 3 or greater adverse event

Countries

United States